SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

OneSource Specialty’s partner gets Health Canada nod for generic version of Ozempic

04 May 2026 Evaluate

OneSource Specialty Pharma’s partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning the company’s partners as the first generic entrants in one of the world’s most significant semaglutide markets.

The step reflects a closely integrated development and manufacturing model. Orbicular led the product development and technical program for the complex peptide, while the company supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from the company’s US FDA-approved flagship facility in Bengaluru.

The approval follows a recent tentative approval in the United States supported by the company, further reinforcing the company’s growing presence in complex peptide-based injectable programs and its ability to support global partners across highly regulated markets.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.

Onesource Specialty Share Price

1748.25 -7.90 (-0.45%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×